This Week in Neurology — Jun 8, 2026

Welcome to This Week in Neurology. This week we're covering 10 notable papers spanning disparities and innovations in epilepsy care, new insights into stroke risk and prevention, and novel approaches to neuro-restoration and diagnostics. Let's dive in.

We begin this week with a focus on epilepsy, starting with a sobering look at health disparities from the journal Neurology. A large, retrospective cohort study using the United States National Inpatient Sample from 2016 to 2021 analyzed over 840,000 epilepsy admissions to investigate the impact of geography on outcomes [10]. After adjusting for a host of demographic, socioeconomic, and hospital factors, the findings were stark: patients from the most rural counties had nearly double the odds of in-hospital mortality compared to those from the most urban counties. They were also more likely to present in status epilepticus and have a prolonged hospital stay. Critically, these disparities were no longer significant when the analysis was restricted to patients with private insurance, strongly suggesting that modifiable structural barriers, not geography itself, are driving these worse outcomes. This paper underscores an urgent need for public health interventions to bridge the care gap for rural populations with epilepsy.

Continuing in epilepsy, another study in Neurology addresses a common and challenging clinical scenario: the use of antiseizure medications during pregnancy [2]. In an Australian cohort study, researchers conducted detailed neuropsychological assessments on 110 children aged 3 to 18. They compared outcomes in children exposed in utero to one of five common monotherapies against an unexposed group. The results provide important guidance for patient counseling. Children prenatally exposed to lamotrigine had cognitive performance comparable to their unexposed peers. In contrast, exposure to valproate, carbamazepine, topiramate, and levetiracetam was associated with lower scores across multiple cognitive domains, including processing speed and academic skills. The largest differences in Full-Scale IQ were seen with topiramate and levetiracetam, with drops of approximately 17 and 14 points, respectively, compared to unexposed children. While the risks of valproate are well-known, these data highlight significant cognitive risks associated with topiramate and, notably, levetiracetam, reinforcing that lamotrigine may be a comparatively safer option regarding neurocognitive outcomes.

Rounding out our epilepsy theme, a meta-analysis in Epilepsia evaluates the promise and current pitfalls of artificial intelligence in analyzing MRI scans for epilepsy care [4]. The analysis, which synthesized data from over 150 studies and more than 26,000 participants, found that AI and machine learning models demonstrate high accuracy across four key clinical applications. These models could distinguish patients with epilepsy from healthy controls with 87% accuracy, lateralize temporal lobe epilepsy with 90% accuracy, localize epileptogenic lesions like focal cortical dysplasia with 82% accuracy, and predict post-surgical seizure freedom with 83% accuracy. However, the authors sound a strong note of caution. A systematic assessment revealed a very high risk of bias across the literature, suggesting these performance estimates may be overly optimistic. Furthermore, most models rely on highly specific, non-standard data acquisition and processing protocols, limiting their real-world clinical deployment. The paper calls for closer collaboration between clinical and data science teams to improve study design and validation.

Next, we turn to cerebrovascular disease. A paper in Neurology investigates the long-term stroke risk associated with migraine in postmenopausal women, a question with previously unclear answers [3]. Using data from over 130,000 participants in the Women's Health Initiative followed for a median of nearly 20 years, researchers found that a history of physician-diagnosed migraine was not associated with total stroke or hemorrhagic stroke. However, it was linked to a significant, albeit modest, 12% higher risk of ischemic stroke. This association held after adjusting for a wide range of cardiovascular and female-specific risk factors. While the study lacked data on aura, the findings suggest that a history of migraine should be considered a contributing risk marker when assessing ischemic stroke risk in postmenopausal women.

In a major clinical trial published in JAMA, the TRACK trial sought to determine if low-dose rivaroxaban could reduce cardiovascular events in patients with advanced chronic kidney disease, a population at extremely high cardiovascular risk [7]. Nearly 1,500 patients with stage 4 or 5 CKD or on dialysis were randomized to receive rivaroxaban 2.5 mg twice daily or placebo. The trial was stopped early for futility. Over a median follow-up of 1.7 years, there was no difference in the primary composite outcome of cardiovascular death, MI, stroke, or a peripheral artery disease event, which occurred in 22.6% of the rivaroxaban group versus 20.7% of the placebo group. In contrast, the risk of major bleeding was significantly increased, occurring in 8.8% of patients on rivaroxaban compared to 6.0% on placebo, translating to a roughly 50% higher risk. This definitive negative trial provides clear evidence that this antithrombotic strategy is not beneficial and is, in fact, harmful in this vulnerable patient population.

Finally in our cerebrovascular section, a study in the Annals of Neurology explores the utility of plasma biomarkers for diagnosing cerebral amyloid angiopathy, or CAA [8]. In a single-center study comparing 186 patients with probable or definite CAA to over 400 controls, researchers found a distinct plasma signature. Patients with CAA had lower concentrations of amyloid-beta 40 and 42, and higher concentrations of phosphorylated-tau 217. Notably, the reduction in amyloid-beta 40 was independent of p-tau levels, suggesting it may be a specific marker. Furthermore, within the CAA group, the levels of these biomarkers correlated with the severity of both hemorrhagic and non-hemorrhagic markers on MRI, such as cortical superficial siderosis and enlarged perivascular spaces. These findings suggest that a panel of plasma biomarkers could one day aid in the non-invasive diagnosis and severity assessment of CAA.

We now shift to novel therapeutics and diagnostics. A landmark feasibility trial in Nature Medicine explores the potential of cervical epidural spinal cord stimulation to restore upper limb function in chronic post-stroke hemiparesis [5]. Seven participants with profound motor deficits were implanted with spinal cord stimulators for four weeks. The procedure was found to be safe, with no serious adverse events. With stimulation turned on, motor function improved immediately, with an average 32% increase in strength. Even with a very low dose of motor activity—only about 5.5 hours with stimulation on—participants demonstrated sustained functional improvements at the end of the study, and spasticity decreased in all of them. The authors note that spared sensory function may be a key determinant of responsiveness. This study provides crucial preliminary evidence for the safety and efficacy of this approach, paving the way for a fully implantable neuroprosthetic solution for post-stroke disability.

In the journal Brain, researchers describe a newly identified autoantibody that may define a treatable autoimmune syndrome mimicking lower motor neuron disease [1]. In a screen of over 3,500 samples, they identified three patients, all initially diagnosed with an ALS variant, who had a distinct autoantibody targeting septin multimers. These antibodies were found to bind to key structures in peripheral nerves, including Schmidt-Lanterman incisures and paranodes. Nerve and skin biopsies showed evidence of inflammation and nerve pathology. While two of the patients died from rapid disease progression with little or no immunotherapy, one patient who received extensive immunotherapy experienced disease stabilization over a three-year period. This discovery suggests that screening for septin multimer autoantibodies should be considered in patients presenting with a severe, motor-predominant neuropathy, as it may identify a rare but treatable condition otherwise mistaken for a fatal neurodegenerative disease.

Finally, we briefly touch on two foundational science papers. A study in Nature provides a detailed map of the genetic and cellular changes that drive the progression of IDH-mutant gliomas [9]. By analyzing tumors from the same patients over time, they identified two main pathways of malignant progression: one driven by acquired genetic changes leading to more proliferative cells, and another linked to an inflammatory, mesenchymal-like state associated with macrophage infiltration. And in Science, a study in mice reveals how memory reactivation during sleep shapes sleep quality itself [6]. Reactivation of negative memories promoted arousal and sleep disturbance, while positive memory reactivation supported stable sleep. This effect was mediated by specific hippocampus-amygdala circuits, and suppressing the reactivation of negative memories restored normal sleep in stressed mice, establishing a direct link between memory content and sleep regulation.

If you only have time for one paper this week, make it the study on in utero exposure to antiseizure medications in Neurology [2]. The findings provide crucial, clinically actionable data for counseling pregnant women with epilepsy, particularly highlighting the significant neurocognitive risks associated with topiramate and levetiracetam, and reinforcing the comparative safety of lamotrigine.

Here are the key takeaways from this week in Neurology. First, for pregnant patients with epilepsy, lamotrigine appears to have a safer neurocognitive profile for the child compared to valproate, topiramate, and notably, levetiracetam. Second, low-dose rivaroxaban should not be used for cardiovascular protection in patients with advanced chronic kidney disease; it increases major bleeding without reducing ischemic events. Third, a history of migraine is a modest risk marker for ischemic, but not hemorrhagic, stroke in postmenopausal women. Fourth, patients with epilepsy residing in rural areas of the United States face significantly worse outcomes, including nearly double the in-hospital mortality, highlighting systemic barriers to care that are not explained by geography alone. And finally, cervical spinal cord stimulation shows early promise for improving upper limb function after stroke, while the discovery of septin multimer autoantibodies may identify a treatable mimic of lower motor neuron disease.

That's your roundup for This Week in Neurology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.